Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $220
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $205 to $220.
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $205 to $220.